Roche Acquires POC MDx Firm Iquum | GenomeWeb

NEW YORK (GenomeWeb News) — Roche said today that it has acquired Iquum, a privately held company developing point-of-care molecular diagnostics.

Under the terms of the agreement, Roche will pay Iquum shareholders $275 million upfront and up to $175 million in contingent product-related milestones. Once the transaction is complete, pending customary closing conditions, Marlborough, Mass.-based Iquum will be integrated into Roche Molecular Diagnostics.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.